![]() ![]() Nanoliposomal dry powder inhaler formulation of Amiloride hydrochloride. Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Latest advances in the development of dry powder inhaler. New aerosol drug delivery systems for the treatment of immune-mediated pulmonary diseases. Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma. The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. Treatment of infection due to Pneumocystis carinii. Pulmonary infectious complications of human immunodeficiency virus infection. Human immunodeficiency virus and respiratory infection. ![]() The investigation provides a practical approach for direct delivery of DS encapsulated in NLs for site specific controlled and prolonged release behavior at the site of action and hence, may play a promising role in prevention of PCP.Į. Developed formulations were found to have in vitro prolonged drug release up to 16 h, and obeys Higuchi's Controlled Release model. Hydrolyzed gelatin based formulation was found to have low density, good flowability, particle size of 7.9 ± 1.1 μm, maximum fine particle fraction (FPF) of 75.6 ± 1.6%, mean mass aerodynamic diameter (MMAD) 2.2 ± 0.1 μm, and geometric standard deviation (GSD) 2.3 ± 0.1. In vitro pulmonary deposition was assessed using Andersen Cascade Impactor as per USP. The resultant dispersion was spray dried and spray dried formulation were characterized to ascertain its performance. NLs were dispersed in phosphate buffer saline (PBS) pH 7.4 containing different carriers like lactose, sucrose, and hydrolyzed gelatin, and 15% l-leucine as antiadherent. DS nano-liposomes (NLs) were separated by ultra centrifugation and characterized. ![]() DS encapsulated liposomes were prepared by thin film evaporation technique and resultant liposomal dispersion was passed through high pressure homogenizer. This investigation was undertaken to evaluate practical feasibility of site specific pulmonary delivery of liposomal encapsulated Dapsone (DS) dry powder inhaler for prolonged drug retention in lungs as an effective alternative in prevention of Pneumocystis carinii pneumonia (PCP) associated with immunocompromised patients. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |